




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C07K 14/47, A61K 38/17, G01N 33/68, A61P 25/28, C12N 5/00, A61K 51/00		A2	(11) International Publication Number: WO 00/68263 (43) International Publication Date: 16 November 2000 (16.11.00)
(21) International Application Number: PCT/CA00/00515 (22) International Filing Date: 4 May 2000 (04.05.00) (30) Priority Data: 60/132,592 5 May 1999 (05.05.99) US (71) Applicant (for all designated States except US): NEUROCHEM, INC. [CA/CA]; 7220 Frederick-Banting, Suite 100, Montréal, Québec H4S 2A1 (CA). (72) Inventors; and (75) Inventors/Applicants (for US only): CHALIFOUR, Robert [CA/CA]; 332 Place Ladouceur, Ile Bizard, Québec H9C 1T4 (CA). GERVAIS, Francine [CA/CA]; 1003 Bellevue, Ile Bizard, Québec H9C 2X5 (CA). GUPTA, Ajay [CA/CA]; 255 St-Louis, Pointe-Claire, Québec H9R 5L6 (CA). (74) Agents: MURPHY, Kevin, P. et al.; Swabey Ogilvy Renault, Suite 1600, 1981 McGill College Avenue, Montréal, Québec H3A 2Y3 (CA).		(81) Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>Without international search report and to be republished upon receipt of that report.</i>	

(54) Title: STEREOSELECTIVE ANTIFIBRILLOGENIC PEPTIDES AND PEPTIDOMIMETICS THEREOF

Protein - Protein Interaction: Targetted Sites



(57) Abstract

The present invention relates to antifibrillogenic agents for inhibiting amyloidosis and/or for cytoprotection for the treatment of amyloidosis disorders. These agents include peptides, isomers thereof and peptidomimetic compounds thereof. These agents comprise a peptide having a sequence identified from the glycosaminoglycan (GAG) binding region and the prot-prot interaction region of the amyloid protein. The peptide has at least one [D] amino acid isomer substitution. The invention also relates to the peptide bound to a label for *in vivo* imaging of amyloid deposits.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

**STEREOSELECTIVE ANTIFIBRILLOGENIC PEPTIDES
AND PEPTIDOMIMETICS THEREOF**

BACKGROUND OF THE INVENTION

5 (a) Field of the Invention

The invention relates to agents having potent antifibrillogenic activity for the treatment of amyloidosis disorders and for imaging of amyloid deposits. These agents include peptides and
10 peptidomimetic compounds thereof.

(b) Description of Prior Art

Amyloidosis refers to a pathological condition characterized by the presence of amyloid fibers. Amyloid is a generic term referring to a group of
15 diverse but specific extracellular protein deposits that are seen in a number of different diseases. Though diverse in their occurrence, all amyloid deposits share common morphologic properties, stain with specific dyes (e.g. Congo red), and have a characteristic red-green
20 birefringent appearance in polarized light after staining. They also share common ultrastructural, x-ray diffraction and infrared spectra features.

Some amyloidotic diseases can be idiopathic but most of these diseases appear as a complication of a
25 previously existing disorder. For example, primary amyloidosis can appear without any other pathology or can follow plasma cell dyscrasia or multiple myeloma. Secondary amyloidosis is usually seen associated with chronic infection (such as tuberculosis) or chronic
30 inflammation (such as rheumatoid arthritis). A familial form of secondary amyloidosis is also seen in Familial Mediterranean Fever (FMF). This familial type of amyloidosis, as one of the other types of familial amyloidosis, is genetically inherited and is found in
35 specific population groups. Isolated forms of amyloidosis are those that tend to involve a single

organ system. Different amyloids are also characterized by the type of protein present in the deposit. For example, neurodegenerative diseases such as scrapie, bovine spongiform encephalitis, 5 Creutzfeldt-Jakob disease and the like are characterized by the appearance and accumulation of a protease-resistant form of a prion protein (referred to as AScr or PrP-27) in the central nervous system. Similarly, Alzheimer's disease, another neurodegenera- 10 tive disorder, is characterized by congophilic cerebral angiopathy, neuritic plaques and neurofibrillary tangles. In this case, the plaque and blood vessel amyloid is formed by the deposition of fibrillar A β amyloid protein. In adult-onset diabetes, amyloids 15 containing the IAPP amyloid protein accumulate in the pancreas. Other systemic diseases, complications of long-term hemodialysis and sequelae of long-standing inflammation or plasma cell dyscrasias are characterized by the accumulation of amyloids 20 systemically. In each of these cases, a different amyloidogenic protein is involved in amyloid deposition.

Once these amyloids have formed, there is no known, widely accepted therapy or treatment that 25 significantly dissolves the deposits *in situ*.

Each amyloidogenic protein has the ability to organize into β -sheet and to form insoluble fibrils that get deposited extracellularly. Each amyloidogenic protein, although different in amino acid sequence has 30 the same property of forming fibrils and binding to other elements such as proteoglycan (glycosaminoglycan), amyloid P and complement component. Moreover, each amyloidogenic protein has amino acid sequences which, although different, will 35 show similarities such as regions with the ability to

bind to GAG's (referred to as the GAG binding site) as well as other regions which will promote β -sheet formation referred to as β -sheet region.

In specific cases, amyloidotic fibrils once
5 deposited can become toxic to the surrounding cells. As per example, the A β fibrils organized as senile plaques have been shown to be associated with dead neuronal cells and microgliosis in patients with Alzheimer's disease. When tested in vitro, A β peptide
10 was shown to be capable of triggering an activation process of the microglia (brain macrophages), which would explain the presence of microgliosis and brain inflammation found in the brain of patients with Alzheimer's disease.

15 In another type of amyloidosis seen in patients with Type II diabetes, the amyloidogenic protein IAPP, has been shown to induce β -islet cell toxicity in vitro. Hence, appearance of IAPP fibrils in the pancreas of Type II diabetic patients could contribute
20 to the loss of the β islet cells (Langerhans) and organ dysfunction.

Particularly, in patients with Alzheimer's Disease, an agent capable 1) of preventing amyloid fibril formation and deposition and 2) of directly or
25 indirectly inhibiting A β -induced neurotoxicity and inflammation (microgliosis), could be a treatment of choice to prevent and arrest the development of Alzheimer's disease.

It would be highly desirable to be provided
30 with agents having potent antifibrillogenic activity for the treatment of amyloidosis disorders.


SUMMARY OF THE INVENTION

One aim of the present invention is to provide agents having potent antifibrillogenic activity for the treatment of amyloidosis disorders.

Another aim of the present invention is to provide a method for the treatment of amyloidosis disorders, such as Alzheimer's' disease.

A number of strategies for possible therapeutic intervention in amyloid development have been proposed. These strategies include reduction of the pool of precursor proteins, prevention of the interaction of precursor proteins and disruption of preformed amyloid. The present invention deals mainly with the second approach, prevention of precursor protein interactions. The ideal molecule to fulfill this function, would interact specifically with the amyloid protein and would in so doing prevent the protein from interacting with itself. When dealing with molecules that are chiral, it is standard practice to identify which of the stereoisomers possesses the activity, since in general, activity can be attributed to one or the other of the isomers. By using a stereochemically pure isomer, side reactions can be avoided or reduced.

In accordance with one embodiment of the present invention there is provided an antifibrillogenic agent for inhibiting amyloidosis and/or for cytoprotection, which comprises a peptide of Formula I, an isomer thereof, a retro or a retro-inverso isomer thereof or a peptidomimetic thereof:



wherein,

Xaa₁ is absent or selected from the group consisting of Lys, Lys-Lys, Xaa₅-Lys-, and Ala;

Xaa₅ is absent or selected from the group consisting of His-Gln-, His-His-Gln-, Val-His-His-Gln-, Glu-Val-His-His-Gln-, Asp-Asp-Asp-, Lys-Val-Asp-Asp-Gln-Asp-, Gln-; Xaa₂ is absent or any amino acid;

5 Xaa₃ is absent, Val or Phe;

Xaa₄ is absent or selected from the group consisting of Phe, Phe-NH₂, Phe-Phe, Phe-Phe-Ala, Phe-Phe-Ala-NH₂, Phe-Phe-Ala-Gln, Phe-Phe-Ala-Gln-NH₂, Val-Leu-Lys, Val-Leu-Lys-NH₂;

10 wherein the peptide of formula I contains at least one Lys or Asp;

and wherein the peptide has at least one [D] amino acid residue,

with the proviso that Lys-Lys-Leu-Val-Phe-Phe-Ala is an all-[D] peptide; and with the proviso that when Xaa₅ is Lys-Val-Asp-Asp-Gln-Asp- all of Xaa₂, Xaa₃, and Xaa₄ are absent.

Preferably, Xaa₂ is a hydrophobic amino acid residue such as a leucine residue.

20 In one embodiment of the invention, the peptide of formula I has at least two [D] amino acid residues, and more preferably at least three [D] amino acid residues. Optionally, the peptide of formula I has one [L] amino acid residue, or more preferably the peptide is an all-[D] isomer peptide.

In another embodiment of the invention, the peptide of Formula I is selected from the group consisting of:

	Lys-Ile-Val-Phe-Phe-Ala	(SEQ ID NO:1);
30	Lys-Lys-Leu-Val-Phe-Phe-Ala	(SEQ ID NO:2);
	Lys-Leu-Val-Phe-Phe-Ala	(SEQ ID NO:3);
	Lys-Phe-Val-Phe-Phe-Ala	(SEQ ID NO:4);
	Ala-Phe-Phe-Val-Leu-Lys	(SEQ ID NO:5);
	Lys-Leu-Val-Phe	(SEQ ID NO:6);
35	Lys-Ala-Val-Phe-Phe-Ala	(SEQ ID NO:7);

Lys-Leu-Val-Phe-Phe (SEQ ID NO:8);
 Lys-Val-Val-Phe-Phe-Ala (SEQ ID NO:9);
 Lys-Ile-Val-Phe-Phe-Ala-NH₂ (SEQ ID NO:10);
 Lys-Leu-Val-Phe-Phe-Ala-NH₂ (SEQ ID NO:11);
 5 Lys-Phe-Val-Phe-Phe-Ala-NH₂ (SEQ ID NO:12);
 Ala-Phe-Phe-Val-Leu-Lys-NH₂ (SEQ ID NO:13);
 Lys-Leu-Val-Phe-NH₂ (SEQ ID NO:14);
 Lys-Ala-Val-Phe-Phe-Ala-NH₂ (SEQ ID NO:15);
 Lys-Leu-Val-Phe-Phe-NH₂ (SEQ ID NO:16);
 10 Lys-Val-Val-Phe-Phe-Ala-NH₂ (SEQ ID NO:17);
 Lys-Leu-Val-Phe-Phe-Ala-Gln (SEQ ID NO:18);
 Lys-Leu-Val-Phe-Phe-Ala-Gln-NH₂ (SEQ ID NO:19);
 His-His-Gln-Lys-Leu-Val-Phe-Phe-Ala-NH₂ (SEQ ID NO:20);
 Asp-Asp-Asp (SEQ ID NO:21);
 15 Lys-Val-Asp-Asp-Gln-Asp (SEQ ID NO:22);
 His-His-Gln-Lys (SEQ ID NO:23);
 and
 Gln-Lys-Leu-Val-Phe-Phe-NH₂ (SEQ ID NO:24).

20 More preferably, the peptide of formula I is a peptide as set forth in SEQ ID NO:2 or SEQ ID NO:3.

In accordance with one embodiment of the present invention there is provided a labeled conjugate for *in vivo* imaging of amyloid plaque, which comprises
 25 a conjugate of formula II:

A-B-C II

wherein A is an amyloid plaque-targeting moiety selected from the group consisting of a peptide of Formula I as defined above, an isomer thereof, a retro
 30 or a retro-inverso isomer thereof and a peptidomimetic thereof,
 wherein B is a linker portion allowing attachment of the amyloid plaque-targeting moiety to C; and
 wherein C is a label that allows for *in vivo* imaging.

Preferably, the linker portion B is selected from the group consisting of Glucose and Phe. Preferably, the label C is ^{99m}Tc .

Still in accordance with the present invention,
5 there is provided a method for the treatment of amyloidosis disorders in a patient, which comprises administering to the patient a therapeutically effective amount of a peptide of Formula I, or the antifibrillogenic agent, as defined above.

10 Further in accordance with the present invention, there is provided a composition for the treatment of amyloidosis disorders in a patient, which comprises a therapeutically effective amount of a peptide of Formula I, or of an antifibrillogenic agent,
15 as defined above in association with a pharmaceutically acceptable carrier.

In accordance with the present invention, there is also provided a composition for *in vivo* imaging of amyloid plaques, which comprises a therapeutically
20 effective amount of a labeled conjugate as defined above in association with a pharmaceutically acceptable carrier.

The peptide of Formula I or the antifibrillogenic agent may be used for inhibiting
25 amyloidosis and/or for cytoprotection.

The labeled conjugate may be used for *in vivo* imaging of amyloid plaques.

The peptide of Formula I or the antifibrillogenic agent may alternatively be used for
30 the manufacture of a medicament for inhibiting amyloidosis and/or for cytoprotection.

Similarly, the labeled conjugate may also be used for the manufacture of a medicament for *in vivo* imaging of amyloid plaques.

Other embodiments of these peptides include racemic mixtures and peptides having mixed chirality, i.e., different chirality at different chiral centers.

In accordance with the peptides Lys-Lys-Leu-Val-Phe-Phe-Ala (SEQ ID NO:2) and Lys-Leu-Val-Phe-Phe-Ala (SEQ ID NO:3), one stereoisomer, the D form, is found to be more active than the L form, and the D isomer is the preferred form for use of this peptide as a drug.

The present invention further provides similar peptides designed for the other amyloidogenic peptides such as AA, AL, and IAPP. In fact, the present invention also provides a peptide for inhibiting amyloidosis and/or for cytoprotection. The peptide has a sequence taken from the β -sheet region of an amyloid protein. Such peptide or a composition containing such peptide can be used for inhibiting amyloidosis and/or for cytoprotection. Alternatively, such peptide or a composition containing such peptide can be used for the manufacture of a medicament for inhibiting amyloidosis and/or for cytoprotection.

Accordingly, the present invention also provides a composition for inhibiting amyloidosis and/or for cytoprotection, which comprises a therapeutically effective amount of a peptide as defined previously in association with a pharmaceutically acceptable carrier.

In accordance with the present invention, the amyloidosis disorder includes, without limitation, prion protein related disorders, type II diabetes and Alzheimer's disease.

With regard to another aspect of the invention, diseases caused by the death or malfunctioning of a particular type or types of cells can be treated by transplanting into the patient

healthy cells of the relevant type of cell. Often these cells are cultured in vitro prior to transplantation to increase their numbers, to allow them to recover after the isolation procedure or to
5 reduce their immunogenicity. However, in many instances the transplants are unsuccessful, due to the death of the transplanted cells. The inventors have now also found that culturing of cells can lead to the formation of fibrils from endogenous proteins. Such
10 fibrils are likely to continue to grow after the cells are transplanted and cause death or dysfunction of the cells. The inventors have also found that the peptide of the present invention or the antifibrillogenic compound of the present invention can be used to reduce
15 the formation of fibrils.

Thus the invention also provides a process for the preparation of cells suitable for transplantation into a mammal, which cells are capable of forming fibrils. The process comprises contacting the cells
20 with the peptide of the present invention or the antifibrillogenic compound of the present invention.

The peptide of Formula I or the antifibrillogenic compound causes breakdown of amyloid deposits which have been formed by the cells prior to
25 the contact. Preferably, the cells are cultured in the presence of the peptide of Formula I or the antifibrillogenic compound.

For the purpose of the present invention the following expressions and terms are defined below.

30 The term "agents having stereoselective antifibrillogenic activity" is intended to mean any peptides, peptide analogues, peptide derivatives, or peptidomimetics which retain the stereoselective antifibrillogenic activity, the cytoprotective and
35 anti-inflammatory activity and/or the ability to alter

a natural amyloidotic protein aggregation as described herein. Peptide analogues, peptide derivatives, or peptidomimetics include any molecules that mimic the chemical structure of a peptide and retain the functional properties of the peptide (Williams, W.V. and Weiner, D.B., eds., Biologically Active Peptides: Design, Synthesis, and Utilization, vol. 1, Technomic Publishing Company Inc., Lancaster, Pa., 1993, pages 35-3..). Examples of peptide analogues, peptide derivatives, or peptidomimetics include compounds with sulfonamide, phosphoramidate or non-amide linkages.

The expression "antifibrillogenic activity" is intended to mean the ability to block or prevent an amyloidogenic protein from forming fibrils, preferably by preventing it from adopting its β -pleated conformation.

The term "cytoprotection" or "cytoprotective activity" is intended to mean the ability to protect cells from amyloid-induced toxicity.

The expression "anti-inflammatory" is intended to mean the ability to block or reduce the $A\beta$ -induced microglial activation process or to block the chemokine-induced inflammatory reaction.

The expression "retro isomer" is intended to mean a reversal of the direction of the peptide backbone.

The expression "inverso isomer" is intended to mean an inversion of the amino acid chirality used to make the peptide.

The expression "retro-inverso isomer" is intended to mean a reversal of both the peptide backbone direction and the amino acid chirality.

Except as otherwise expressly defined herein, the abbreviations used herein for designating the amino acids and the protective groups are based on

recommendations of the IUPAC-IUB Commission on Biochemical Nomenclature (*Biochemistry*, 1972, 11:1726-1732).

Also, unless specified otherwise, the A β (1-40) is the naturally occurring A β (1-40), that is the all [L]-isomer.

BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1 illustrates the targeted sites of the protein-protein interactions required for self-assembly into β -sheet fibrils;

Fig. 2 illustrates a thioflavin T fluorescence assay for fibril formation by [L]-A β (1-40) in the absence and presence of a peptide in accordance with one embodiment of the invention;

Fig. 3 shows the same assay as in Fig. 2 for fibril formation by [D]-A β (1-40);

Fig. 4 is a bar graph illustrating the percentage of thioflavin T fluorescence in the presence of the [D]-peptide used in Fig. 2, with or without single substitutions of corresponding [L]-amino acids;

Fig. 5 is a bar graph illustrating a thioflavin T fluorescence assay for fibril formation by [L]-A β (1-40) in the presence of the [D]-peptide used in Fig. 2, with or without substitution of the Leu residue by other hydrophobic amino acids;

Fig. 6 illustrates the toxicity of [L]-A β (1-40) in the absence and presence of peptides in accordance with one embodiment of the invention; and

Fig. 7 is a bar graph illustrating the toxicity of [L]-A β (1-40) in the presence of another peptide of the present invention.

DETAILED DESCRIPTION OF THE INVENTION

As illustrated in Fig. 1, internal regions of the A β sequence have been shown to confer characteristics of the amyloid protein. Indeed, the region between amino acid 13-16 (His-His-Gln-Lys, SEQ ID NO:23) of the amyloid protein is responsible for the interaction between the A β protein and the glycosaminoglycan moiety of the proteoglycans (Kisilevsky, R., et al., Proteoglycans and amyloid fibrillogenesis: The nature and origin of amyloid fibrils, Wiley, Chichester (*CIBA Foundation Symposium* 1997), pp. 58-72). Proteoglycans are known to promote amyloid fibril formation as well as protect these fibrils from proteolysis (Gupta-Bansal, R., et al., 1995, *The Journal of Biological Chemistry*, 270:18666-18671). More recently, the same region has been determined to play a role in the activation process of microglial cells by A β (Giulian, D., et al., 1998, *The Journal of Biological Chemistry*, 273(45):29719-29726). This 13-16 region of A β , often referred to as the GAG binding site, is also part of a larger domain, the 10-16 region of the protein which has been suggested as the region responsible for the adherence of A β to the cell surface (Giulian, D., et al., 1996, *The Journal of Neuroscience*, 16(19):6021-6037). Such adherence of A β to the cell surface will allow the interaction of A β with the specific cells leading to either microglia activation or toxicity of neuronal cells.

These two overlapping regions of the A β protein, i.e. amino acids 13-16 and 10-16 are adjacent to the 16-21 region of A β , a short hydrophobic stretch critical for the formation of fibrillar structures (Hilbrich, C., et al., 1992, *J. Mol. Biol.*, 228:460-473). By having peptides capable of interacting with these overlapping regions of A β , one can aim at

preventing both A β fibril formation and A β cellular interaction (i.e. microglia activation, neurotoxicity).

A preferred embodiment of the present invention is novel and arises from the unexpected finding that
5 the all-[D] stereoisomer peptides, Lys-Lys-Leu-Val-Phe-Phe-Ala (SEQ ID NO:2) and Lys-Leu-Val-Phe-Phe-Ala (SEQ ID NO:3), are much more potent inhibitors of A β (1-40) fibrillogenesis than the corresponding all-[L] peptides. The all-[D] stereoisomer peptides, Lys-Lys-
10 Leu-Val-Phe-Phe-Ala (SEQ ID NO:2) and Lys-Leu-Val-Phe-Phe-Ala (SEQ ID NO:3) are also potent cytoprotective agents.

This finding was unforeseen particularly because the researchers who originally reported
15 peptides containing the sequence Lys-Leu-Val-Phe-Phe-Ala (SEQ ID NO:3) as an inhibitor of fibrillogenesis, state in a second article which they published: "A peptide entirely composed of amino acids in D configuration with the sequence klvff (lowercase marks
20 amino acids in D configuration) was synthesized using the SPOT technique and assayed for ¹²⁵I-LBMP1620 binding. This peptide failed to bind ¹²⁵I-LBMP1620 indicating that KLVFF-KLVFF interaction is stereospecific." Tjernberg, L.O. et al. (1997)
25 Controlling Amyloid β -Peptide Fibril Formation with Protease-stable Ligands, *J. Biol. Chem.*, 272:12602.

Inhibition of Amyloidosis

The experimental work performed leading to this
30 invention included comparing the ability of the [D] and [L] stereoisomers of peptide Lys-Lys-Leu-Val-Phe-Phe-Ala (SEQ ID NO:2) to inhibit the fibrillogenesis process observed with the amyloidogenic peptide A β (1-40) in a thioflavin T fluorescence assay.

The thioflavin T fluorescence assay for fibrillogenesis is based on the principle that the fluorescent dye, thioflavin T, binds specifically to fibrillar, but not to unaggregated A β peptide (LeVine
5 III, H., 1993, *Protein Science* 2:404-410). Upon binding, thioflavin T develops a characteristic fluorescence (Naiki, H., et al., 1996, *Lab. Invest.* 74: 374-383) which can be easily detected. The dye is believed to interact with the stacked cross- β pleated
10 sheets, the common structural motif of all amyloids (LeVine III, H., 1995, *Amyloid: Int. J. Exp. Clin Invest.* 2:1.6). Thioflavin T is widely used to assay the effect of compounds on A β peptide fibrillogenesis (Bronfman, P.C., et al., 1995, *Neuroscience Lett.*
15 218:201-203).

In this assay test compounds are incubated with a solution of A β (1-40) (20 μ M) containing 10 μ M thioflavin T, in 0.02M Tris/0.02M acetate/0.15M NaCl/0.005% azide/pH 7.40 at 37°C in sealed 384 well
20 microplates. Readings (ex 430 nm/em 485nm) are taken at various time intervals with a microplate fluorescence reader. An increase in fluorescence signifies the appearance of amyloid or intermediates in the production of amyloid. Inhibitors of fibrillogenesis
25 will lead to less fluorescence production.

The results illustrated in Table 1 below, are based on the fluorescence production in the presence of test peptides at either 20 μ M or 80 μ M concentration, at the time intervals of 5, 19, 45, 67, 77 and 90
30 hours, compared to a control, buffer alone, without added inhibitory peptide.

Table 1
Order Of Potency of Peptide Inhibitors

	Tested at 20 μ M	Tested at 80 μ M
(strongest activity)	1 (D) KIVFFA	1 (D) AFFVLK
	2 (D) KKLVFFA	1 (D) KKLVFFA
	3 (D) KLVFFA	1 (D) KLVFFA
	4 (D) KLVFFA	1 (D) KLVFFA
	5 (D) AFFVLK	5 (D) KIVFFA
	6 (D) KLVF	6 (D) KAVFFA
	7 (D) KAVFFA	7 (L) KKLVFFA
	8 (L) KLVFFA	8 (L) KLVFFA
	9 (D) KLVFF	9 (D) KLVF
	10 (L) KKLVFFA	10 (D) KLVFF
(weakest activity)	11 (L) AFFVLK	11 (L) AFFVLK

Protocol

A β peptide: A β (1-40) 95% purity (American Peptide Company, Inc, Sunnyvale, Cal. USA, cat. 62-0-78) is
 5 disaggregated in trifluoroacetic acid and filtered through a 0.02 μ M filter, (Whatman Anotop 25 plus, .02 μ m, Catalogue no. 6809 4102) in hexafluoroisopropanol (HFIP). Solutions of A β (1-40) at 600 μ M in HFIP are stored at -80°C.

10 Assay mixture: The mixture is prepared as two solutions that are combined upon addition to the 384 well microplate (Corning Costar cat. 3705).

- i) Solution A consists of test peptides in 0.02M Tris/0.02M acetate/0.15M NaCl/0.01 % azide at
 15 pH 7.40 or buffer alone (control),
- ii) Solution B consists of A β (1-40) 40 μ M, thioflavin T 20 μ M in 0.02M Tris/0.02M acetate/0.15M NaCl at pH 7.40. This solution is prepared by drying the A β peptide under

nitrogen and then resuspending this in 0.04M Tris base with 15 minutes sonication. An equal volume of 0.04M acetic acid containing 0.3 M NaCl is added and the solution is adjusted to pH 7.40 \pm 0.02. A small volume of 5mM thioflavin T is added to the solution to give a final 20 μ M concentration of thioflavin T.

iii) The microplate is loaded with 40 μ L of solution A followed by 40 μ L of solution B which gives a final 20 μ M A β (1-40), 10 μ M thioflavin T, and either 20 μ M, 80 μ M or 100 μ M test compound in 0.02M Tris/0.02M acetate/0.15M NaCl/0.005% azide, pH 7.40. The plate is sealed and loaded into the microplate fluorescence reader.

Fluorescence measurement data analysis: The HTS-7000 Bio Assay Reader, Perkin Elmer, is used to perform kinetic runs of about 5 days. Readings were taken at various time intervals, 5, 19, 45, 67, 77 and 90 hours, with one minute shaking before each reading. Bandpass filters used were: excitation 430 nm, emission 485 nm.

Calculations

The rank order of efficacy of the peptides is determined by observing which peptides allow the appearance of fluorescence, above the background level, first. For example in the presence of buffer control alone, fluorescence appears earlier than when any of the peptides is present. The most active peptides prevent the appearance of fluorescence even after 90 hours of incubation.

The results achieved in the thioflavin T fibrillogenesis assays show that all-[D] stereoisomer peptide was about 60 times more potent than the all-[L] stereoisomer peptide. This is based on the observation that 400 μ M all-[L] stereoisomer was required to give

an equivalent inhibition to that produced with 6.1 μM all-[D] stereoisomer peptide.

The results achieved in the A β -NBD environmental probe fibrillogenesis assay showed that
5 the all-[D] stereoisomer peptide was at least 30 times more potent than the all-[L] stereoisomer peptide. This estimate is based on the observation that the lowest concentration of all-[D] peptide tested (25 μM) was more potent than the highest concentration of the all-
10 [L] peptide (800 μM).

β -sheet and GAG binding domains peptides

Novel peptides and peptidomimetics that include complementary sequences to certain portions of amyloidogenic peptides such as A β , AA, AL, IAPP, and
15 prion proteins are designed to be capable of inhibition of Protein-Protein interactions or self assembly. The targeted portions in the various disease-causing proteins aforementioned, preferably contain one or more charged residues such as aspartate, glutamate, lysine,
20 histidine and arginine. Such peptides and their peptidomimetics will inhibit fibrillogenesis of the amyloidogenic peptides and prion proteins and interfere with chemokines binding to the cell surface proteoglycans leading to dimerization or
25 tetramerization by interacting with their GAG binding domains. In the case of A β , these interactions lead to cytoprotection as well as inhibition of inflammatory response and serve as potent therapeutics for the treatment of Alzheimer's disease. In the case of
30 chemokine-related disorders these interactions may lead to a decrease in the uncontrolled inflammatory response associated with some diseases.

Other amyloidogenic peptides such as IAPP, have also been tested. For example, 2 peptides from the
35 β -sheet region of IAPP have been shown to inhibit IAPP

fibril formation using the thioflavin T fluorescence assay, circular dichroism (measures secondary structure) and the electron microscope (to look at fibrils directly).

5 The full-length IAPP is 37 amino acids and the β -sheet region is the 20-29 sequence. The 20-29 sequence is critical for forming β -sheet and has been previously shown to be a key region in modulating IAPP aggregation and folding. Hexapeptides from this β -
10 sheet region were examined and 2 were found to be active.

 Hexapeptides spanning the 20-29 region (Ser-Asn-Asn-Phe-Gly-Ala-Ile-Leu-Ser-Ser) of the IAPP protein were synthesized and tested for their ability
15 to prevent fibril formation as determined by circular dichroism and the thioflavin T assay. Hexapeptides were designed and were found to be capable of blocking the formation of IAPP fibrils. These peptides (Ser-Asn-Asn-Phe-Gly-Ala- and Asn-Asn-Phe-Gly-Ala-Ile) were
20 directed towards the central core of the 20-29 region.

 Novel peptides containing 3-6 residues that are complementary (in terms of their charges) to the 10-16 segment of A β peptide have been shown for the first time to strongly interact with A β peptide. They provide
25 a starting point for the design of BBB (blood brain barrier) permeable peptidomimetics. In principle, the present invention provides similar peptides can be designed for the other amyloidogenic peptides such as AA, AL, and IAPP.

30 Asp-Asp-Asp (SEQ ID NO:21), a tripeptide, when incubated with A β 40 under physiological conditions shows a slight decrease at time t=0 in the amount of β -sheet content as is evident by the CD spectrum. Incubation of this tripeptide with A β 40 for 24 hours
35 shows no trace of β -sheet conformation of the A β 40 and

clearly indicates the ability of this tripeptide to strongly interact with A β 40 peptide and keep A β 40 in a randomized and non-fibrillary conformation. The anti-fibrillogenic property of this tripeptide is also supported by the A β 42 solubilization assay.

Lys-Val-Asp-Asp-Gln-Asp (SEQ ID NO:22), a hexapeptide, when incubated with A β 40 under physiological conditions shows an increase at time t=0 in the amount of β -sheet content as is evident by the CD spectrum. Incubation of this hexapeptide with A β 40 for 24 hours shows a dramatic increase in β -sheet content of the A β 40 and clearly indicates the ability of this hexapeptide to strongly interact with A β 40 peptide and organize it into a β -sheet conformation. Electron microscopy of the mixture failed to show any fibrils indicating that this particular compound is in fact an anti-fibrillogenic compound with regard to A β . In vitro results with NBD and thioflavin-T based fluorescence assays confirm this finding. It is the understanding of the inventors that this interesting observation will lead to a greater understanding of fibrillogenesis of A β 40 and A β 42 peptides and as a result, will provide important information for the design of potent anti-fibrillogenic compounds for A β , other amyloidotic peptides such as AA, AL and IAPP for the treatment of diseases such as Alzheimer's, Type II Diabetes and amyloidosis related disorders. The same principle can also be applied to the design of peptide type compounds for the inhibition of binding of various chemokines to the cell surface as well as inhibition of self assembly and cellular adherence of prion proteins.

The results illustrated in Fig. 2 show that all [D]-Lys-Leu-Val-Phe-Phe-Ala (SEQ. ID NO: 3) is a more potent inhibitor of A β (1-40) assembly in the thioflavin T fluorescence assay than is all [L]-Lys-

Leu-Val-Phe-Phe-Ala. Since the naturally occurring A β (1-40) used in these experiments was the all-[L] amino acid version, these results indicate that an inhibitor peptide works best when containing amino acids of the opposite chirality.

Fig. 3 demonstrates that the same rule of opposite chirality illustrated in Fig. 2 applies for the assembly of A β (1-40) synthesized using amino acids of the [D] type. In this experiment all-[L]-Lys-Leu-Val-Phe-Phe-Ala (SEQ. ID NO:3) is a more potent inhibitor in the all-[D]-A β (1-40) assembly reaction than all-[D]-Lys-Leu-Val-Phe-Phe-Ala. This result confirms that peptides of opposite chirality are better inhibitors.

Fig. 4 illustrates the inhibition of A β (1-40) fibril formation by all-[D]-Lys-Leu-Val-Phe-Phe-Ala (20 μ M) with or without single substitutions of [L]-amino acids in the thioflavin T fluorescence assay. In this experiment the ability of the all-[D]-Lys-Leu-Val-Phe-Phe-Ala peptide to inhibit A β (1-40) fibril formation, measured as percentage of thioflavin T fluorescence in the absence of peptide (control), was compared to [D]-Lys-Leu-Val-Phe-Phe-Ala peptides with single [L]-amino acid replacements. None of the mixed chirality Lys-Leu-Val-Phe-Phe-Ala peptides were more potent than the original all-[D] peptide. This result demonstrates that [D]-amino acids are more potent inhibitors of A β (1-40) fibrillogenesis than [L]-amino acids.

However as seen in Fig. 4 some peptides with single [L] substitutions do retain inhibitory activity. In particular peptides in which the [D] isomer of the Lys, the second Phe and the Ala are substituted with the [L]-isomers retain inhibitory activity. The substitutions, which reduce inhibitory activity the

most, are the Leu, the Val and the first Phe, indicating that these residues contribute the most to the potency of the [D]-peptide. From Fig. 4, it is apparent that peptides with mixed chirality or with at least one [D]-substituted amino acid are also inhibitors, although not as potent as the all-[D] peptide. These mixed-chirality peptides are thus meant to be included in the present invention.

Fig. 5 illustrates the inhibition of A β (1-40) fibril formation in the thioflavin T fluorescence assay by all-[D]-Lys-Leu-Val-Phe-Phe-Ala (20 μ M), with or without replacement of the leucine by other hydrophobic amino acids. In this experiment all the peptides tested retained some inhibitory activity. This result demonstrates that the leucine residue is not critical for inhibition of A β fibril formation in the all-[D] peptide. These results illustrated in Fig. 5 were non-obvious and unexpected in light of a prior publication which identified the Leucine residue as critical in an all-[L] version of the peptide (Tjernberg LO et al., *J. Biol. Chem.* 271:8545, 1996).

Cytoprotection

The experimental work performed leading to this invention also included comparing the ability of [D] and [L] stereoisomers of the peptides of the present invention to show cytoprotective activity, i.e. to protect cells from A β toxicity.

Figure 6 uses the MTT assay on SH-SY5Y cells.

Protocol

A SH-SY5Y human neuroblast cell line (American Type Culture Collection, cat. CRL-2266) is cultured according to technical specifications. Monomerized A β (1-40) is prepared using trifluoroacetic acid and hexafluoroisopropanol, in the same way already described for the thioflavin T fluorescence assay.

Monomerized A β at various concentrations in TANA buffer (0.02 M TRIS base pH 7.4, 0.02M acetate, 0.15 M NaCl) is added to 100 μ M test peptide and the mixture is incubated for 24 hours at 37°C with agitation, in order to allow polymerization to occur. Cells are adhered to a 96-well microplate for 2 hours at 37°C and 5% CO₂ before the A β -peptide mixture, or buffer alone (control), is added. The microplate is gently agitated and incubated for 20-24 hours at 37°C and 5% CO₂. Cell viability is determined by a MTT-based colorimetric assay. The MTT assay (Boehringer Mannheim, Cell Proliferation Kit 1) is based on the principle that the yellow tetrazolium salt MTT is cleaved in metabolically-active cells to produce purple formazan crystals. The formazan crystals are solubilized and the resulting colored solution is quantified using a scanning multiwell spectrophotometer (ELISA reader, Absorbance A₅₆₀ nm). Cellular toxicity was calculated as follows:

$$\text{Toxicity (\%)} = 100 - \frac{(\text{O.D. sample} - \text{O.D. Blank})}{(\text{O.D. Control} - \text{O.D. Blank})}$$

Figure 6 shows the neurotoxicity of A β (1-40) in the absence or presence of various peptides of the present invention. In this experiment the all-[D]-Lys-Lys-Leu-Val-Phe-Phe-Ala (SEQ. ID NO: 2) peptide is a more potent inhibitor of A β neurotoxicity than the all-[L]-Lys-Lys-Leu-Val-Phe-Phe-Ala peptide in the cytoprotection assay.

Figure 7 uses the propidium iodide assay on primary cortical neurons. Briefly, fetal rat primary cortical neurons are isolated and cultured according to Durkin, J.P. et al., J. Neurochem., 66:951-962, 1996. Neurons are plated in a 48 well microplate. 7 days after plating the neuronal culture media is supplemented with B27 (Life Technologies, Data sheet

form No. 3755). A mixture of A β and test peptide is added to the cortical neurons for 3 days at 37°C and 5% CO₂.


5 Cell viability is then visually assessed as the proportion of phase-bright cells that exclude propidium iodide, since only dead cells take up propidium iodide.

Figure 7 shows the potent cytoprotective activity of all-[D]-Lys-Leu-Val-Phe-Phe-Ala (SEQ ID NO:3). This experiment shows the potent cytoprotective
10 activity of all-[D]-Lys-Leu-Val-Phe-Phe-Ala compared to Congo red, which is a known cytoprotective agent and compared to the absence of any cytoprotective agent (A β alone).

While the invention has been described in
15 connection with specific embodiments thereof, it will be understood that it is capable of further modifications and this application is intended to cover any variations, uses, or adaptations of the invention following, in general, the principles of the invention
20 and including such departures from the present disclosure as come within known or customary practice within the art to which the invention pertains and as may be applied to the essential features hereinbefore set forth, and as follows in the scope of the appended
25 claims.

WHAT IS CLAIMED IS:

1. An antifibrillogenic agent for inhibiting amyloidosis and/or for cytoprotection, which comprises a peptide of Formula I, an isomer thereof, a retro or a retro-inverso isomer thereof or a peptidomimetic thereof:



wherein,

Xaa₁ is absent or selected from the group consisting of Lys, Lys-Lys, Xaa₅-Lys-, and Ala;

Xaa₅ is absent or selected from the group consisting of His-Gln-, His-His-Gln-, Val-His-His-Gln-, Glu-Val-His-His-Gln-, Asp-Asp-Asp-, Lys-Val-Asp-Asp-Gln-Asp-, Gln-;

Xaa₂ is absent or any amino acid;

Xaa₃ is absent, Val or Phe;

Xaa₄ is absent or selected from the group consisting of Phe, Phe-NH₂, Phe-Phe, Phe-Phe-Ala, Phe-Phe-Ala-NH₂, Phe-Phe-Ala-Gln, Phe-Phe-Ala-Gln-NH₂, Val-Leu-Lys, Val-Leu-Lys-NH₂;

wherein said peptide of formula I contains at least one Lys or Asp;

and wherein said peptide has at least one [D] amino acid residue,

with the proviso that Lys-Lys-Leu-Val-Phe-Phe-Ala is an all-[D] peptide; and with the proviso that when Xaa₅ is Lys-Val-Asp-Asp-Gln-Asp- all of Xaa₂, Xaa₃, and Xaa₄ are absent.

2. The antifibrillogenic agent of claim 1, wherein Xaa₂ is a hydrophobic amino acid residue.

3. The antifibrillogenic agent of claim 1, wherein the peptide of formula I has at least two [D] amino acid residues.

4. The antifibrillogenic agent of claim 1, wherein the peptide of formula I has at least three [D] amino acid residues.

5. The antifibrillogenic agent of claim 1, wherein the peptide of formula I has one [L] amino acid residue.

6. The antifibrillogenic agent of claim 1, wherein the peptide of formula I is an all-[D] isomer peptide.

7. The antifibrillogenic agent of claim 1, 2, 3, 4, 5, or 6, wherein said peptide of Formula I is selected from the group consisting of:

Lys-Ile-Val-Phe-Phe-Ala	(SEQ ID NO:1);
Lys-Lys-Leu-Val-Phe-Phe-Ala	(SEQ ID NO:2);
Lys-Leu-Val-Phe-Phe-Ala	(SEQ ID NO:3);
Lys-Phe-Val-Phe-Phe-Ala	(SEQ ID NO:4);
Ala-Phe-Phe-Val-Leu-Lys	(SEQ ID NO:5);
Lys-Leu-Val-Phe	(SEQ ID NO:6);
Lys-Ala-Val-Phe-Phe-Ala	(SEQ ID NO:7);
Lys-Leu-Val-Phe-Phe	(SEQ ID NO:8);
Lys-Val-Val-Phe-Phe-Ala	(SEQ ID NO:9);
Lys-Ile-Val-Phe-Phe-Ala-NH ₂	(SEQ ID NO:10);
Lys-Leu-Val-Phe-Phe-Ala-NH ₂	(SEQ ID NO:11);
Lys-Phe-Val-Phe-Phe-Ala-NH ₂	(SEQ ID NO:12);
Ala-Phe-Phe-Val-Leu-Lys-NH ₂	(SEQ ID NO:13);
Lys-Leu-Val-Phe-NH ₂	(SEQ ID NO:14);
Lys-Ala-Val-Phe-Phe-Ala-NH ₂	(SEQ ID NO:15);
Lys-Leu-Val-Phe-Phe-NH ₂	(SEQ ID NO:16);
Lys-Val-Val-Phe-Phe-Ala-NH ₂	(SEQ ID NO:17);
Lys-Leu-Val-Phe-Phe-Ala-Gln	(SEQ ID NO:18);
Lys-Leu-Val-Phe-Phe-Ala-Gln-NH ₂	(SEQ ID NO:19);
His-His-Gln-Lys-Leu-Val-Phe-Phe-Ala-NH ₂	(SEQ ID NO:20);
Asp-Asp-Asp	(SEQ ID NO:21);

Lys-Val-Asp-Asp-Gln-Asp (SEQ ID NO:22);
His-His-Gln-Lys (SEQ ID NO:23);
and
Gln-Lys-Leu-Val-Phe-Phe-NH₂ (SEQ ID NO:24).

8. The antifibrillogenic agent of claim 1, wherein the peptide of formula I is a peptide as set forth in SEQ ID NO:2 or SEQ ID NO:3.

9. A labeled conjugate for *in vivo* imaging of amyloid deposits, which comprises a conjugate of formula II:

A-B-C II

wherein A is an amyloid plaque-targeting moiety selected from the group consisting of a peptide of Formula I as defined in claim 1, an isomer thereof, a retro or a retro-inverso isomer thereof and a peptidomimetic thereof,
wherein B is a linker portion allowing attachment of the amyloid plaque-targeting moiety to C; and
wherein C is a label that allows for said *in vivo* imaging.

10. The labeled conjugate of claim 9, wherein Xaa, in Formula I is a hydrophobic amino acid residue.

11. The labeled conjugate of claim 9, wherein the peptide of formula I has at least two [D] amino acid residues.

12. The labeled conjugate of claim 9, wherein the peptide of formula I has at least three [D] amino acid residues.

13. The labeled conjugate of claim 9, wherein the peptide of formula I has one [L] amino acid residue.

14. The labeled conjugate of claim 9, wherein the peptide of formula I is an all-[D] isomer peptide.

15. The labeled conjugate of claim 9, 10, 11, 12, 13 or 14, wherein said peptide of Formula I is selected from the group consisting of:

Lys-Ile-Val-Phe-Phe-Ala	(SEQ ID NO:1);
Lys-Lys-Leu-Val-Phe-Phe-Ala	(SEQ ID NO:2);
Lys-Leu-Val-Phe-Phe-Ala	(SEQ ID NO:3);
Lys-Phe-Val-Phe-Phe-Ala	(SEQ ID NO:4);
Ala-Phe-Phe-Val-Leu-Lys	(SEQ ID NO:5);
Lys-Leu-Val-Phe	(SEQ ID NO:6);
Lys-Ala-Val-Phe-Phe-Ala	(SEQ ID NO:7);
Lys-Leu-Val-Phe-Phe	(SEQ ID NO:8);
Lys-Val-Val-Phe-Phe-Ala	(SEQ ID NO:9);
Lys-Ile-Val-Phe-Phe-Ala-NH ₂	(SEQ ID NO:10);
Lys-Leu-Val-Phe-Phe-Ala-NH ₂	(SEQ ID NO:11);
Lys-Phe-Val-Phe-Phe-Ala-NH ₂	(SEQ ID NO:12);
Ala-Phe-Phe-Val-Leu-Lys-NH ₂	(SEQ ID NO:13);
Lys-Leu-Val-Phe-NH ₂	(SEQ ID NO:14);
Lys-Ala-Val-Phe-Phe-Ala-NH ₂	(SEQ ID NO:15);
Lys-Leu-Val-Phe-Phe-NH ₂	(SEQ ID NO:16);
Lys-Val-Val-Phe-Phe-Ala-NH ₂	(SEQ ID NO:17);
Lys-Leu-Val-Phe-Phe-Ala-Gln	(SEQ ID NO:18);
Lys-Leu-Val-Phe-Phe-Ala-Gln-NH ₂	(SEQ ID NO:19);
His-His-Gln-Lys-Leu-Val-Phe-Phe-Ala-NH ₂	(SEQ ID NO:20);
Asp-Asp-Asp	(SEQ ID NO:21);
Lys-Val-Asp-Asp-Gln-Asp	(SEQ ID NO:22);
His-His-Gln-Lys	(SEQ ID NO:23);
and	
Gln-Lys-Leu-Val-Phe-Phe-NH ₂	(SEQ ID NO:24).

16. The labeled conjugate of claim 15, wherein B is selected from the group consisting of Glucose and Phe.

17. The labeled conjugate of claim 15, wherein C is ^{99m}Tc.

18. A method for the treatment of amyloidosis disorders in a patient, which comprises administering to said patient a therapeutically effective amount of a peptide of Formula I as defined in claim 1, 2, 3, 4, 5, 6, 7 or 8.

19. A method for the treatment of amyloidosis disorders in a patient, which comprises administering to said patient a therapeutically effective amount of an antifibrillogenic agent as defined in claim 1, 2, 3, 4, 5, 6, 7 or 8.

20. A composition for the treatment of amyloidosis disorders in a patient, which comprises a therapeutically effective amount of a peptide of Formula I as defined in claim 1, 2, 3, 4, 5, 6, 7 or 8 in association with a pharmaceutically acceptable carrier.

21. A composition for the treatment of amyloidosis disorders in a patient, which comprises a therapeutically effective amount of an antifibrillogenic agent as defined in claim 1, 2, 3, 4, 5, 6, 7 or 8 in association with a pharmaceutically acceptable carrier.

22. A composition for in vivo imaging of amyloid deposits, which comprises a therapeutically effective amount of a labeled conjugate as defined in claim 9,

10, 11, 12, 13, 14, 15, 16 or 17 in association with a pharmaceutically acceptable carrier.

23. Use of a peptide of Formula I as defined in claim 1, 2, 3, 4, 5, 6, 7 or 8 for inhibiting amyloidosis and/or for cytoprotection.

24. Use of an antifibrillogenic agent as defined in claim 1, 2, 3, 4, 5, 6, 7 or 8 for inhibiting amyloidosis and/or for cytoprotection.

25. Use of a labeled conjugate as defined in claim 10, 11, 12, 13, 14, 15, 16 or 17 for *in vivo* imaging of amyloid deposits.

26. Use of a peptide of Formula I as defined in claim 1, 2, 3, 4, 5, 6, 7 or 8 for the manufacture of a medicament for inhibiting amyloidosis and/or for cytoprotection.

27. Use of an antifibrillogenic agent as defined in claim 1, 2, 3, 4, 5, 6, 7 or 8 for the manufacture of a medicament for inhibiting amyloidosis and/or for cytoprotection.

28. Use of a labeled conjugate as defined in claim 10, 11, 12, 13, 14, 15, 16 or 17 for the manufacture of a medicament for *in vivo* imaging of amyloid deposits.

29. A peptide, an isomer thereof, a retro or a retro-inverso isomer thereof or a peptidomimetic thereof, for inhibiting amyloidosis and/or for cytoprotection, said peptide having a sequence taken from the β -sheet region of an amyloid protein.

30. Use of a peptide as defined in claim 29 for inhibiting amyloidosis and/or for cytoprotection.

31. Use of a peptide as defined in claim 29 for the manufacture of a medicament for inhibiting amyloidosis and/or for cytoprotection.

32. A composition for inhibiting amyloidosis and/or for cytoprotection, which comprises a therapeutically effective amount of a peptide as defined in claim 31, 30 or 31 in association with a pharmaceutically acceptable carrier.


33. Use of a labeled peptide as defined in claim 29 for the manufacture of a medicament for *in vivo* imaging of amyloid deposits.

34. A process for the preparation of cells suitable for transplantation into a mammal, which cells are capable of forming amyloid deposits, said process comprising contacting the cells *in vitro* with the peptide of Formula I as defined in claim 1 or with the antifibrillogenic compound as defined in claim 1, 2, 3, 4, 5, 6, 7 or 8 for inhibiting amyloid deposit formation.


35. Process according to claim 34, wherein said peptide of Formula I or said antifibrillogenic compound causes breakdown of amyloid deposits, the deposits having been formed by said cells prior to said contact.

36. Process according to claim 34 or 35, in which the cells are cultured in the presence of the peptide of Formula I or the antifibrillogenic compound.


Protein - Protein Interaction: Targetted Sites




2/7




3/7




4/7



5/7



6/7






FIG. 7

SEQUENCE LISTING

<110> NEUROCHEM INC.
CHALIFOUR, Robert
GERVAIS, Francine
GUPTA, Ajay

<120> STEREOSELECTIVE ANTIFIBRILLOGENIC
PEPTIDES AND PEPTIDOMIMETICS THEREOF

<130> 14228-1PCT

<150> US 60/132,592

<151> 1999-05-05

<160> 24

<170> FastSEQ for Windows Version 3.0

<210> 1

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> peptide having antifibrillogenic activity and/or
cytoprotection

<400> 1

Lys Ile Val Phe Phe Ala
1 5

<210> 2

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> peptide having antifibrillogenic activity and/or
cytoprotection

<400> 2

Lys Lys Leu Val Phe Phe Ala
1 5

<210> 3

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> peptide having antifibrillogenic activity and/or
cytoprotection

<400> 3

Lys Leu Val Phe Phe Ala

1 5

<210> 4
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> peptide having antifibrillogenic activity and/or
cytoprotection

<400> 4
Lys Phe Val Phe Phe Ala
1 5

<210> 5
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> peptide having antifibrillogenic activity and/or
cytoprotection

<400> 5
Ala Phe Phe Val Leu Lys
1 5

<210> 6
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> peptide having antifibrillogenic activity and/or
cytoprotection

<400> 6
Lys Leu Val Phe
1

<210> 7
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> peptide having antifibrillogenic activity and/or
cytoprotection

<400> 7
Lys Ala Val Phe Phe Ala
1 5

<210> 8
<211> 5
<212> PRT

<213> Artificial Sequence

<220>

<223> peptide having antifibrillogenic activity and/or
cytoprotection

<400> 8

Lys Leu Val Phe Phe
1 5

<210> 9

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> peptide having antifibrillogenic activity and/or
cytoprotection

<400> 9

Lys Val Val Phe Phe Ala
1 5

<210> 10

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> peptide having antifibrillogenic activity and/or
cytoprotection

<221> AMIDATION

<222> (6)...(6)

<400> 10

Lys Ile Val Phe Phe Ala
1 5

<210> 11

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> peptide having antifibrillogenic activity and/or
cytoprotection

<221> AMIDATION

<222> (6)...(6)

<400> 11

Lys Leu Val Phe Phe Ala
1 5

<210> 12

<211> 6

<212> PRT
<213> Artificial Sequence

<220>
<223> peptide having antifibrillogenic activity and/or
cytoprotection

<221> AMIDATION
<222> (6)...(6)

<400> 12
Lys Phe Val Phe Phe Ala
1 5

<210> 13
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> peptide having antifibrillogenic activity and/or
cytoprotection

<221> AMIDATION
<222> (6)...(6)

<400> 13
Ala Phe Phe Val Leu Lys
1 5

<210> 14
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> peptide having antifibrillogenic activity and/or
cytoprotection

<221> AMIDATION
<222> (4)...(4)

<400> 14
Lys Leu Val Phe
1

<210> 15
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> peptide having antifibrillogenic activity and/or
cytoprotection

<221> AMIDATION
<222> (6)...(6)

<400> 15
Lys Ala Val Phe Phe Ala
1 5

<210> 16
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> peptide having antifibrillogenic activity and/or
cytoprotection

<221> AMIDATION
<222> (5)...(5)

<400> 16
Lys Leu Val Phe Phe
1 5

<210> 17
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> peptide having antifibrillogenic activity and/or
cytoprotection

<221> AMIDATION
<222> (6)...(6)

<400> 17
Lys Val Val Phe Phe Ala
1 5

<210> 18
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> peptide having antifibrillogenic activity and/or
cytoprotection

<400> 18
Lys Leu Val Phe Phe Ala Gln
1 5

<210> 19
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> peptide having antifibrillogenic activity and/or

cytoprotection

<221> AMIDATION

<222> (7)...(7)

<400> 19

Lys Leu Val Phe Phe Ala Gln
1 5

<210> 20

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> peptide having antifibrillogenic activity and/or
cytoprotection

<221> AMIDATION

<222> (9)...(9)

<400> 20

His His Gln Lys Leu Val Phe Phe Ala
1 5

<210> 21

<211> 3

<212> PRT

<213> Artificial Sequence

<220>

<223> peptide having antifibrillogenic activity and/or
cytoprotection

<400> 21

Asp Asp Asp
1

<210> 22

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> peptide having antifibrillogenic activity and/or
cytoprotection

<400> 22

Lys Val Asp Asp Gln Asp
1 5

<210> 23

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> peptide having antifibrillogenic activity and/or
cytoprotection

<400> 23

His His Gln Lys

1

<210> 24

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> peptide having antifibrillogenic activity and/or
cytoprotection

<221> AMIDATION

<222> (6)...(6)

<400> 24

Gln Lys Leu Val Phe Phe

1

5

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
16 November 2000 (16.11.2000)

PCT

(10) International Publication Number
WO 00/68263 A3

- (51) International Patent Classification⁷: **C07K 14/47**,
A61K 38/17, G01N 33/68, A61P 25/28, C12N 5/00,
A61K 51/00
- (74) Agents: **MURPHY, Kevin, P.** et al.: Swabey Ogilvy Renault, Suite 1600, 1981 McGill College Avenue, Montréal, Québec H3A 2Y3 (CA).
- (21) International Application Number: **PCT/CA00/00515**
- (22) International Filing Date: **4 May 2000 (04.05.2000)**
- (25) Filing Language: **English**
- (26) Publication Language: **English**
- (30) Priority Data:
60/132,592 **5 May 1999 (05.05.1999)** **US**
- (71) Applicant (for all designated States except US): **NEUROCHEM, INC.** [CA/CA]; 7220 Frederick-Banting, Suite 100, Montréal, Québec H4S 2A1 (CA).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **CHALIFOUR, Robert** [CA/CA]; 332 Place Ladouceur, Ile Bizard, Québec H9C 1T4 (CA). **GERVAIS, Francine** [CA/CA]; 1003 Bellevue, Ile Bizard, Québec H9C 2X5 (CA). **GUPTA, Ajay** [CA/CA]; 255 St-Louis, Pointe-Claire, Québec H9R 5L6 (CA).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:**
— *With international search report.*
- (88) Date of publication of the international search report:
3 May 2001
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

WO 00/68263 A3

(54) Title: **STEREOSELECTIVE ANTIFIBRILLOGENIC PEPTIDES AND PEPTIDOMIMETICS THEREOF**

(57) Abstract: The present invention relates to antifibrillogenic agents for inhibiting amyloidosis and/or for cytoprotection for the treatment of amyloidosis disorders. These agents include peptides, isomers thereof and peptidomimetic compounds thereof. These agents comprise a peptide having a sequence identified from the glycosaminoglycan (GAG) binding region and the prot-prot interaction region of the amyloid protein. The peptide has at least one [D] amino acid isomer substitution. The invention also relates to the peptide bound to a label for *in vivo* imaging of amyloid deposits.

INTERNATIONAL SEARCH REPORT

Internatio. Application No

PCT/CA 00/00515

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07K14/47 A61K38/17 G01N33/68 A61P25/28 C12N5/00
A61K51/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07K A61K G01N C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

CHEM ABS Data, WPI Data, PAJ, BIOSIS, MEDLINE, EPO-Internal

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 98 08868 A (PRAECIS PHARM INC) 5 March 1998 (1998-03-05) the whole document	1-7, 9-36
Y	TJERNBERG L O ET AL: "CONTROLLING AMYLOID BETA-PEPTIDE FIBRIL FORMATION WITH PROTEASE-STABLE LIGANDS" JOURNAL OF BIOLOGICAL CHEMISTRY, US, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, vol. 272, no. 19, 9 May 1997 (1997-05-09), pages 12601-12605, XP002050230 ISSN: 0021-9258 cited in the application See especially Fig.3	1-7, 9-36



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

5 December 2000

Date of mailing of the international search report

29.12.2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Groenendijk, M

INTERNATIONAL SEARCH REPORT

Internatio Application No

PCT/CA 00/00515

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 96 28471 A (PHARM PEPTIDES INC) 19 September 1996 (1996-09-19) the whole document ---	1-7, 9-36
A	GIULIAN E.A.: "The HHQK domain of beta-amyloid provides a structural basis for the immunopathology of Alzheimer disease" JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 273, no. 45, 6 November 1998 (1998-11-06), pages 29719-29726, XP002146049 MD US cited in the application the whole document ---	1-7, 9-36
A	WO 97 21728 A (KAROLINSKA INNOVATIONS AB ;NORDSTEDT CHRISTER (SE); NAESLUND JAN ()) 19 June 1997 (1997-06-19) the whole document ---	
A	DATABASE WPI Section Ch, Week 199837 Derwent Publications Ltd., London, GB; Class B04, AN 1998-433888 XP002154640 -& JP 10 182695 A (TEIKOKU SEIYAKU KK), 7 July 1998 (1998-07-07) page 6 ---	1-7, 18-21, 23, 24, 26, 27, 29-32
A	KOERNYEI J ET AL: "TC-99M LABELLING AND BIODISTRIBUTION OF DESIGNED MOLECULES" RADIOACTIVE ISOTOPES IN CLINICAL MEDICINE AND RESEARCH, BIRKHAUSER VERLAG, BASEL, CH, 1995, pages 287-292, XP000965479 see especially table 2 ---	1-7, 9, 11-15, 17, 22, 25, 28, 33
A	TORNEIRO E.A.: "Sequence-elective binding of peptides in water by a synthetic receptor molecule" JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 117, no. 21, 1995, pages 5887-5888, XP002154639 DC US see especially Table 1 -----	

INTERNATIONAL SEARCH REPORT

International application No.
PCT/CA 00/00515

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 18,19,23-25 and 30 are directed to a method of treatment of the human/animal body or to a diagnostic method practised on the human/animal body the search has been carried out and based on the alleged effects of the compound/composition.
2. ☒ Claims Nos.: 1-6,9-36(partially)
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☒ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☒ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/SA/ 210

Continuation of Box I.2

Claims Nos.: 1-6,9-36(partially)

Present claims 1 and 29 relate to peptides or isomers thereof lacking any constant structural domain and almost any definition of the constituting amino acid residues (due to the facultative presence of all constituting Xaa's in formula I and the absence of any structural definition in claim 29), which peptides are defined by reference to desirable characteristics or properties, namely that they inhibit amyloidosis and/or are cytoprotective. Due to the facultative presence of all constituting Xaa's in formula I

The claims cover all compounds having these characteristics or properties, whereas the application provides support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for only a very limited number of such compounds. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the compounds by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to the compounds defined in the claims 7 and 8 and their conjugates as defined in claim 9, their compositions and use.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

FURTHER INFORMATION CONTINUED FROM PCT/SA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 8(complete),1-7,9-36(partially)

Compounds having the structure defined in claim 7, SEQ ID NO: 1-20,23 and 24,their compositions and use

2. Claims: 1-7,9-36(partially)

Compounds having the structure defined in claim 7, SEQ ID NO:21 and 22, their compositions and use

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/CA 00/00515

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9808868 A	05-03-1998	AU 4238797 A EP 0929574 A US 5985242 A	19-03-1998 21-07-1999 16-11-1999
WO 9628471 A	19-09-1996	US 5817626 A US 5854215 A AU 5252496 A CA 2214247 A EP 0815134 A JP 11514333 T US 5854204 A US 5985242 A	06-10-1998 29-12-1998 02-10-1996 19-09-1996 07-01-1998 07-12-1999 29-12-1998 16-11-1999
WO 9721728 A	19-06-1997	AU 1072897 A EP 0866805 A	03-07-1997 30-09-1998
JP 10182695 A	07-07-1998	NONE	

THIS PAGE BLANK (USPTO)